⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7887727 | 0.97 | EPHX2 (0.39) | — | |
| SCHEMBL18768478 | 0.97 | EPHX2 (0.44) | — | |
| SCHEMBL12166550 | 0.84 | EPHX2 (0.37) | — | |
| SCHEMBL17835194 | 0.84 | EPHX2 (0.37) | — | |
| SCHEMBL17835198 | 0.84 | EPHX2 (0.37) | — | |
| SCHEMBL24754447 | 0.84 | EPHX2 (0.37) | — | |
| SCHEMBL14731959 | 0.84 | EPHX2 (0.37) | — | |
| SCHEMBL17835276 | 0.84 | EPHX2 (0.37) | — | |
| SCHEMBL19619775 | 0.84 | EPHX2 (0.37) | — | |
| SCHEMBL23637950 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109647199-A | A kind of preparation method of reverse osmosis membrane and thus obtained reverse osmosis membrane | 时代沃顿科技有限公司 | 2019-04-19 | — | — | CN | claimed |
| WO-2024008722-A2 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2024-01-11 | — | — | WO | disclosed |
| CN-114682102-B | Reverse osmosis membrane and preparation method thereof | 沃顿科技股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-114682102-A | Reverse osmosis membrane and preparation method thereof | 沃顿科技股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-112892249-A | Polyamide reverse osmosis membrane and preparation method thereof | 时代沃顿科技有限公司 | 2021-06-04 | — | — | CN | disclosed |
| WO-2019160884-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-22 | — | — | WO | disclosed |
| CN-109647199-A | A kind of preparation method of reverse osmosis membrane and thus obtained reverse osmosis membrane | 时代沃顿科技有限公司 | 2019-04-19 | — | — | CN | disclosed |
| WO-2018071447-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
| US-20170080054-A1 | Derivatisation of Granulocyte Colony-Stimulating Factor | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2017-03-23 | — | — | US | disclosed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| EP-2174931-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-20100069499-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100056640-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-2151431-A1 | AMIDE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2010-02-10 | — | — | EP | disclosed |
| EP-2143709-A1 | AMIDE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2010-01-13 | — | — | EP | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
| EP-0707585-A1 | BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES | PFIZER INC. (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001980-A1 | BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES | PFIZER INC. (US) | 1995-01-19 | — | — | WO | disclosed |